Guardian Pharmacy (GRDN) Soars 9.1%: Is Further Upside Left in the Stock?

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks Guardian Pharmacy (GRDN) Soars 9.1%: Is Further Upside Left in the Stock? March 31, 2026 — 05:32 am EDT Written by Zacks Equity Research for Zacks-> Guardian Pharmacy Services (GRDN) shares rallied 9.1% in the last trading session to close at $37.25. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.9% gain over the past four weeks.Guardian Pharmacy Services’ stock price gain reflects growing investor confidence in the strength of its product portfolio. Investors are increasingly valuing its differentiated, service-oriented model within the long-term care pharmacy market. The company’s integrated offerings—combining medication dispensing, clinical pharmacy support, and proprietary technology platforms, such as Guardian Compass and medication analytics tools—position it as a data-driven healthcare solutions provider. This tech-enhanced portfolio supports better patient outcomes and cost efficiencies for care facilities, which is driving client expansion, higher retention, and stronger revenue visibility.This provider of pharmacy services to long-term care facilities is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of +14.3%. Revenues are expected to be $329.68 million, up 0.1% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Guardian Pharmacy, the consensus EPS estimate for the quarter has been revised 4.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on GRDN going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Guardian Pharmacy is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Akebia Therapeutics (AKBA), finished the last trading session 1.5% lower at $1.32. AKBA has returned 2.3% over the past month.For Akebia Therapeutics, the consensus EPS estimate for the upcoming report has changed -233.3% over the past month to -$0.01. This represents a change of -133.3% from what the company reported a year ago. Akebia Therapeutics currently has a Zacks Rank of #5 (Strong Sell). Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportGuardian Pharmacy Services, Inc. (GRDN) : Free Stock Analysis ReportAkebia Therapeutics, Inc. (AKBA) : Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Zacks Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com. More articles by this source-> Stocks mentioned GRDN AKBA More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.